Auricularia and Atherosclerosis Prevention

Wood Ear Heart Health

2 IU/mg

The specific anticoagulant activity of purified Auricularia polysaccharide, which inhibited platelet aggregation comparable to aspirin in rat studies.

Yoon et al., Thrombosis Research, 2003

3 Risk Factors

targeted: coagulation, cholesterol, lipids

Aspirin-Like Effect

on platelet aggregation in ex vivo rat test

0 Human Trials

all evidence is preclinical

Yoon et al., Thrombosis Research, 2003

View as image ↗

Atherosclerosis, the buildup of plaques inside arterial walls, is driven by a convergence of high cholesterol, chronic inflammation, oxidative stress, and blood clotting dysfunction. Auricularia auricula (wood ear mushroom) has been investigated for its effects on several of these risk factors in preclinical models. The research spans anticoagulant polysaccharides, cholesterol-lowering ethanol extracts, and lipid metabolism modulation through gut microbiota. Five studies published between 2003 and 2023 provide the evidence base. None have been tested in human clinical trials for cardiovascular outcomes.

For related cardiovascular research, see wood ear and cholesterol: lipid-lowering effects and wood ear for heart health: cardiovascular research review. For the anticoagulant research specifically, see wood ear and anticoagulant polysaccharides: nature's blood thinner.

Anticoagulant Polysaccharides: The Earliest Cardiovascular Finding

The foundational cardiovascular study on Auricularia came from Yoon et al. (2003), who isolated an acidic polysaccharide from Auricularia auricula using water, alkali, and acid extractions.^[1] The alkali extract showed the highest anticoagulant activity. After gel filtration chromatography purification, the polysaccharide had a specific anticoagulant activity of 2 IU/mg and an average molecular mass of approximately 160 kDa.

The polysaccharide contained mainly mannose, glucose, glucuronic acid, and xylose but no sulfate esters. This is notable because most known polysaccharide anticoagulants (like heparin) rely on sulfate groups for their activity. The Auricularia polysaccharide used a different mechanism: it catalyzed thrombin inhibition by antithrombin but did not enhance inhibition by heparin cofactor II. Factor Xa inhibition by antithrombin was not affected.

Chemical modification confirmed the structural requirements: when glucuronic acid carboxyl groups were chemically reduced, anticoagulant activity disappeared. This means the uronic acid residues are essential for the anticoagulant mechanism.

In ex vivo tests, rats orally fed the polysaccharide showed inhibited platelet aggregation comparable to aspirin, a well-established antiplatelet agent. This oral bioavailability finding is important because many polysaccharides are poorly absorbed from the gastrointestinal tract. The authors suggested these polysaccharides "may constitute a new source of compounds with action on coagulation, platelet aggregation and, perhaps, on thrombosis."

The "perhaps" is appropriate caution. A single rat study showing aspirin-like platelet inhibition in ex vivo tests does not establish clinical anticoagulant utility. The dose, bioavailability in humans, and interaction with existing anticoagulant medications remain completely unknown.

Cholesterol Reduction: Polyphenols Beyond Polysaccharides

Chen et al. (2011) shifted focus from polysaccharides to polyphenolic compounds, testing an ethanol extract of Auricularia (AAE) containing more than 16% polyphenolic compounds by weight.^[2] The extraction method specifically excluded polysaccharides, water-soluble fiber, and protein, isolating the polyphenol fraction.

Thirty-six ICR mice were divided into three groups: normal diet, cholesterol-enriched diet (CED), and CED plus AAE at 150 mg/kg/day for 8 weeks. The AAE group showed:

• Decreased total cholesterol
• Decreased atherosclerosis index (the ratio of total cholesterol minus HDL-C to HDL-C)
• Increased HDL-C (the "good" cholesterol)
• Increased fecal excretion of bile acids
• Improved antioxidant status

No effects were observed on triglycerides, LDL-C, or fecal neutral cholesterol excretion.

The increased fecal bile acid excretion is mechanistically important. Bile acids are synthesized from cholesterol in the liver. When more bile acids are excreted rather than reabsorbed, the liver must draw down cholesterol stores to synthesize replacements, lowering circulating cholesterol. This is the same mechanism by which bile acid sequestrant drugs (cholestyramine, colesevelam) work in humans.

The fact that polyphenols, not polysaccharides, drove this effect expands the picture of Auricularia's cardiovascular relevance. Previous research had attributed cholesterol-lowering effects primarily to polysaccharides and fiber. Chen et al. demonstrated that non-polysaccharide components carry independent activity.

Lipid Metabolism: From Fat Cells to Gene Expression

Reza et al. (2015) conducted the most mechanistically detailed lipid study, testing Auricularia 70% ethanol extract (AAE) both in vivo and in vitro.^[3]

In the in vivo arm, male C57BL/6 mice received normal or high-fat diets with or without AAE at 0.1%, 0.3%, and 1% (w/w). AAE-supplemented groups showed:

• Reduced body weight and adipose tissue mass
• Dose-dependent decreases in plasma lipids and liver enzymes
• Prevention of hepatic steatosis (fatty liver)

The in vitro work in mouse 3T3-L1 adipocytes revealed the molecular mechanism. AAE suppressed expression of three key adipogenic and lipogenic genes:

• PPARgamma (peroxisome proliferator-activated receptor gamma), the master regulator of fat cell differentiation
• C/EBPalpha (CCAAT/enhancer-binding protein alpha), which works with PPARgamma to drive adipogenesis
• FAS (fatty acid synthase), the enzyme that synthesizes fatty acids

This gene suppression occurred without cytotoxicity, meaning AAE reduced lipid accumulation by altering cellular programming rather than killing fat cells. The authors concluded AAE "may reduce the risk of hepatic steatosis by modulating plasma lipids via the regulation of adipogenic/lipogenic transcriptional factors."

For atherosclerosis prevention, the combined cholesterol reduction (Chen et al., 2011) and lipogenesis suppression (Reza et al., 2015) address two major plaque-building pathways: circulating lipids and tissue lipid accumulation.

The Gut-Liver-Cardiovascular Connection

More recent research connects Auricularia's gut microbiome effects to cardiovascular risk factors through bile acid signaling.

Shu et al. (2023) showed Auricularia polysaccharides modulated gut microbiota in NAFLD mice, enriching Lactobacillus and Bifidobacterium.^[4] This microbial shift altered bile acid profiles, increasing deoxycholic acid and activating the Farnesoid X receptor (FXR). FXR activation reduces hepatic lipid accumulation and improves bile acid metabolism, both relevant to atherosclerosis risk.

Xu et al. (2021) demonstrated that Auricularia polysaccharides at 50 and 100 mg/kg improved glycolipid metabolism in diabetic mice while reshaping gut microbiota composition.^[5] The gut bacterial changes correlated with decreased inflammation, lower insulin resistance, and reduced liver injury. Type 2 diabetes itself is a major risk factor for atherosclerosis, and the lipid metabolism improvements observed through gut modulation represent another pathway by which Auricularia could influence cardiovascular risk.

This gut-liver-cardiovascular axis adds biological plausibility to the direct cholesterol and anticoagulant findings. Rather than isolated effects, the evidence suggests Auricularia compounds may influence multiple interconnected systems. For the full gut microbiome evidence, see Auricularia and gut microbiome modulation.

Multiple Compounds, Multiple Pathways

The atherosclerosis-relevant research on Auricularia involves at least three distinct compound classes:

Acidic polysaccharides (160 kDa, mannose/glucose/glucuronic acid backbone) provide anticoagulant activity through antithrombin-mediated thrombin inhibition.^[1]

Polyphenolic compounds (>16% of ethanol extract) drive cholesterol reduction through increased fecal bile acid excretion.^[2]

Prebiotic polysaccharides modulate gut microbiota composition, altering bile acid metabolism and FXR signaling.^[4]

These compounds can be isolated separately, but whole mushroom consumption would deliver all three simultaneously. Whether the combined effect is additive, synergistic, or involves interactions between pathways has not been studied.

This multi-compound profile distinguishes Auricularia from single-target cardiovascular interventions. Statins lower cholesterol through HMG-CoA reductase inhibition. Aspirin inhibits platelet aggregation through COX-1. Each addresses one risk factor. Auricularia, at least in rodent models, simultaneously affects coagulation, cholesterol metabolism, lipogenesis, and gut-mediated bile acid signaling. Whether this breadth translates to genuine multi-target cardiovascular protection or simply reflects the nonspecific effects of a complex natural extract containing hundreds of compounds remains an open question.

The atherosclerosis index reduction observed by Chen et al. (2011) is worth contextualizing.^[2] This ratio (total cholesterol minus HDL-C divided by HDL-C) captures both the harmful and protective fractions of cholesterol. Auricularia extract simultaneously lowered the numerator (total cholesterol) and raised the denominator (HDL-C), producing a doubly favorable shift in the ratio. In human epidemiology, the atherosclerosis index is a better predictor of cardiovascular events than total cholesterol alone. However, improvements in this marker in mice do not guarantee similar improvements in humans, and the predictive value of mouse lipid ratios for human cardiovascular outcomes is limited.

The Reza et al. (2015) finding that Auricularia extract suppresses PPARgamma and C/EBPalpha without cytotoxicity is mechanistically interesting because these are the same transcription factors targeted by thiazolidinedione drugs (pioglitazone, rosiglitazone).^[3] However, thiazolidinediones activate PPARgamma to improve insulin sensitivity, while Auricularia extract suppresses it to reduce lipid accumulation. These opposing actions on the same transcription factor could have complex interactions in organisms with both insulin resistance and dyslipidemia, a combination common in metabolic syndrome.

What the Evidence Does Not Show

No human cardiovascular data exist. Every study used mice or rats. The transition from rodent lipid metabolism to human cardiovascular disease prevention is a large and uncertain step.

No atherosclerosis imaging or plaque measurement. The studies measured surrogate markers (cholesterol levels, platelet aggregation, liver lipids, gene expression) rather than actual atherosclerotic plaque formation or regression. Surrogate markers do not always predict clinical outcomes.

The anticoagulant finding is from a single study. Yoon et al. (2003) demonstrated aspirin-like platelet inhibition, but this has not been replicated in 20 years. The interaction between Auricularia polysaccharides and pharmaceutical anticoagulants (warfarin, direct oral anticoagulants) is completely unknown, which represents a potential safety concern for individuals already on blood-thinning medications.

Dose translation is problematic. Mouse doses of 150 mg/kg/day ethanol extract or 100 mg/kg polysaccharide do not translate to human doses through simple body weight scaling. Pharmacokinetic data for Auricularia compounds in humans do not exist.

Long-term safety for cardiovascular use is untested. Atherosclerosis develops over decades. The longest study ran 8 weeks. Chronic effects, tolerance development, and long-term safety profiles are unknown.

Strain and species variation is unexamined. All studies used Auricularia auricula or Auricularia auricula-judae, but different Auricularia species (A. polytricha, A. cornea) may have different compound profiles and biological activities. Even within A. auricula, growing conditions, substrate, and processing methods likely affect polysaccharide structure and polyphenol content. No standardization exists for cardiovascular research-grade Auricularia preparations.

For blood pressure effects specifically, see wood ear and blood pressure: antihypertensive research.

The Bottom Line

Auricularia auricula contains compounds that address multiple atherosclerosis risk factors in preclinical models. Acidic polysaccharides show anticoagulant activity through antithrombin-mediated thrombin inhibition with aspirin-like platelet effects in rats. Polyphenolic extracts lower cholesterol through increased bile acid excretion. Ethanol extracts suppress adipogenic gene expression, preventing lipid accumulation. Prebiotic polysaccharides modulate gut microbiota to alter bile acid metabolism through FXR signaling. The multi-target profile is biologically plausible for cardiovascular protection, but no human clinical data exist, and the gap between rodent lipid markers and human atherosclerosis outcomes remains unbridged.

Frequently Asked Questions

Can wood ear mushroom prevent atherosclerosis?

Preclinical research shows wood ear mushroom compounds address several atherosclerosis risk factors in mice and rats: anticoagulant polysaccharides inhibit platelet aggregation (Yoon et al., 2003), ethanol extracts lower total cholesterol and raise HDL-C (Chen et al., 2011), and polysaccharides modulate lipid metabolism through gut microbiota (Shu et al., 2023). No human clinical trials have tested wood ear for atherosclerosis prevention or cardiovascular outcomes. The evidence is entirely preclinical.

Is wood ear mushroom a natural blood thinner?

A purified polysaccharide from Auricularia auricula showed anticoagulant activity of 2 IU/mg and inhibited platelet aggregation comparable to aspirin in rat ex vivo tests (Yoon et al., 2003). The mechanism involves thrombin inhibition through antithrombin, using glucuronic acid residues rather than the sulfate groups found in heparin. This is a single preclinical study; the effect has not been confirmed in humans, and interactions with pharmaceutical blood thinners are unknown.

Does wood ear mushroom lower cholesterol?

In ICR mice fed a cholesterol-enriched diet, Auricularia ethanol extract at 150 mg/kg/day for 8 weeks decreased total cholesterol and the atherosclerosis index while increasing HDL-C and fecal bile acid excretion (Chen et al., 2011). A separate study showed Auricularia extract suppressed lipogenic gene expression in fat cells (Reza et al., 2015). The cholesterol-lowering effect appears to involve polyphenolic compounds, not just the polysaccharides traditionally credited. No human cholesterol trials have been conducted.

How does Auricularia auricula affect cardiovascular risk factors?

Research identifies three mechanisms targeting cardiovascular risk: anticoagulant polysaccharides that inhibit thrombin via antithrombin (Yoon et al., 2003); polyphenols that increase fecal bile acid excretion, lowering circulating cholesterol (Chen et al., 2011); and prebiotic polysaccharides that reshape gut microbiota, altering bile acid profiles and FXR signaling to reduce liver lipid accumulation (Shu et al., 2023). Whether these mechanisms work additively in whole mushroom consumption is unknown.

Is it safe to eat wood ear mushroom while taking blood thinners?

No clinical data exist on interactions between Auricularia and pharmaceutical anticoagulants such as warfarin, rivaroxaban, or apixaban. One preclinical study found Auricularia polysaccharides inhibited platelet aggregation comparable to aspirin in rats (Yoon et al., 2003). The interaction between mushroom-derived anticoagulant polysaccharides and standard anticoagulant medications has not been studied. This represents a gap in the safety data.

What compounds in wood ear mushroom affect heart health?

At least three compound classes are involved. Acidic polysaccharides (160 kDa, containing mannose, glucose, glucuronic acid, and xylose) provide anticoagulant activity (Yoon et al., 2003). Polyphenolic compounds (>16% of ethanol extract) lower cholesterol via bile acid excretion (Chen et al., 2011). Prebiotic polysaccharides modulate gut bacteria to influence bile acid metabolism and FXR signaling (Shu et al., 2023). The polyphenol finding was unexpected, as earlier research attributed cholesterol effects primarily to polysaccharides.

Sources & References

1. 1RTHM-00065·Yoon, Seon-Joo et al. (2003). “The nontoxic mushroom Auricularia auricula contains a polysaccharide with anticoagulant activity mediated by antithrombin..” Thrombosis research.Study breakdown →PubMed →↩
2. 2RTHM-00208·Chen, Gang et al. (2011). “Hypocholesterolemic effects of Auricularia auricula ethanol extract in ICR mice fed a cholesterol-enriched diet..” Journal of food science and technology.Study breakdown →PubMed →↩
3. 3RTHM-00399·Reza, Md Ahsanur et al. (2015). “Hypolipidemic and Hepatic Steatosis Preventing Activities of the Wood Ear Medicinal Mushroom Auricularia auricula-judae (Higher Basidiomycetes) Ethanol Extract In Vivo and In Vitro..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
4. 4RTHM-00852·Shu, Yifan et al. (2023). “The polysaccharides from Auricularia auricula alleviate non-alcoholic fatty liver disease via modulating gut microbiota and bile acids metabolism..” International journal of biological macromolecules.Study breakdown →PubMed →↩
5. 5RTHM-00728·Xu, Nuo et al. (2021). “Auricularia auricula-judae (Bull.) polysaccharides improve type 2 diabetes in HFD/STZ-induced mice by regulating the AKT/AMPK signaling pathways and the gut microbiota..” Journal of food science.Study breakdown →PubMed →↩